jarbes ChangeLog

Version 1.7.2 -- February-March 2019
  * New function: "gesmix"" performs the finite mixture random effects bias
  analysis of Verde 2017 and Verde and Curcio 2019.
  * New arguments for the function "ges":
      EmBi = "Empirical Bias"standing for "penalization of observational studies"
      ExPe = "Explicit Penalization" for observational studies.
  * All if()s 've been checked. The reason was:
    Issue from CRAN compilation:
    --- failure: length > 1 in coercion to logical ---

Version 1.7.1 -- December 2018
  * A bug in function hmr() is fixed.

Version 1.7.0 -- June 2018
  * Implementation of the function "hmr" for combining aggregated data and
  individual participant data.
  * New dataset "healing": this dataset corresponds to a systematic review of
  aggregated data. The primary endpoint is healing without amputation in one
  year follow up.
  * New dataset "healingipd": This dataset corresponds to individual
  participant data for diabetic patients.

Version 1.1.0		-- December 2017
  * Implementation of the "ges" function for Generalized Evidence Synthesis.
  * Implementation of Half Cauchy priors for components of variances.
  * Implementation of Empirical Bias adjustement for Observational Studies.
  * Implementation of Penalization methods for Observationa Studies.
  * First prototype of the "hmr" function for combining IPD and AD data.

Version 1.0.0		-- September 2017
  * Implementation of the "metarisk"" function for bivariate hierarchical
    meta-regression of aggregated data.
  * Documentation improved.

Version 0.5.0 -- January 2017
  * Creation of data examples:
  * ppv.cap: PPV23 (23-valent pneumococcal polysaccharide vaccine) with 16 Randomized
    Clinical Trials (RCTs); outcome variable CAP (community-acquired pneumonia).

  * ppv.ipde: PPV23 with 3 RCTs and observational studies (5 cohorts and 3 case
    controls); all data types are aggregated results; outcome variable IPD
    (invasive pneumococcal disease).

  * stem.cells: 31 randomized controlled trials (RCTs) of two treatment groups of
    heart disease patients, where the treatment group received bone marrow stem
    cells and the control group a placebo treatment.

  * opti: one pragmatic trial, the OPTIMIZE trial, which evaluates the clinical
    effectiveness of a perioperative, cardiac output–guided hemodynamic therapy
    algorithm.
    And 21 small RCTs with evaluation of Risk of Bias. All are studies have
    aggregated data.

  * foot.ad: 36 RCTs which investigate adjunctive therapies vs. routine medical care in
    diabetic patients. The primary outcome is healing without foot amputation. There
    are aggregated covariates describing studies and patients characteristics.

  * foot.ipd: A cohort study with 260 diabetic patients, the outcome variable is
    healing without amputation in a followup of one year. In addition we have 14
    potential risk factors.






